A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Blinatumomab (Primary)
- Indications Acute biphenotypic leukaemia
- Focus Therapeutic Use
- 14 Mar 2024 Planned End Date changed from 1 Nov 2024 to 1 Aug 2027.
- 14 Dec 2023 Planned End Date changed from 1 Nov 2025 to 1 Nov 2024.
- 14 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 30 Jun 2024.